Hospira (HSP +3.7%) shares surge on a report that a U.S. district court invalidated...

|By:, SA News Editor

Hospira (HSP +3.7%) shares surge on a report that a U.S. district court invalidated Sanofi-Aventis' (SNY -2.1%) patent on Taxotere, potentially opening the door for its generic version of the cancer treatment. The drug was one of Sanofi's top revenue producers, with $2.2B in sales in 2009.